BRAF and neoplasm: To confirm these findings, we performed IGFBP2 immunohistochemistry (IHC) on treatment-naive tumor biopsies from 34 melanoma patients (21 BRAFV600E/K and 13 non-BRAF mutant tissues) (Supplementary Data 5).